glp-1 gip tirzepatide Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Tirzepatide (TZP) differentially induces internalization

doi:10.1016/S0378-4274(01)00396-4

Risks and Side Effects Like any medication, Ozempic comes with potential side effects

Medicaid GLP-1 Coverage in 2026, By the Numbers 13 state Medicaid programs cover GLP-1s for obesity, down from 16 in October 2025 (KFF) About 7.8 million of 39.5 million adult enrollees, under 20 percent, live in a covered state Medicaid GLP-1 prescriptions grew from about 1 million in 2019 to over 8 million in 2024 Gross Medicaid GLP-1 spending reached nearly 9 billion dollars in 2024, before rebates of roughly 40 percent Nearly 40 percent of adults on Medicaid have obesity, which is why the cost math keeps breaking 9 states changed their coverage status in the past 12 months, affecting about 35 percent of enrollees How Medicaid GLP-1 Coverage Works in 2026 Federal Medicaid law requires states to cover nearly all FDA-approved drugs

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)

J., Godin, A

Beenken, A